These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 28097091)

  • 1. Evaluation of novel protease inhibitors against darunavir-resistant variants of HIV type 1.
    Inoue M; Oyama D; Hidaka K; Kameoka M
    FEBS Open Bio; 2017 Jan; 7(1):88-95. PubMed ID: 28097091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. C-5-Modified Tetrahydropyrano-Tetrahydofuran-Derived Protease Inhibitors (PIs) Exert Potent Inhibition of the Replication of HIV-1 Variants Highly Resistant to Various PIs, including Darunavir.
    Aoki M; Hayashi H; Yedidi RS; Martyr CD; Takamatsu Y; Aoki-Ogata H; Nakamura T; Nakata H; Das D; Yamagata Y; Ghosh AK; Mitsuya H
    J Virol; 2015 Nov; 90(5):2180-94. PubMed ID: 26581995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short communication: Phenotypic protease inhibitor resistance and cross-resistance in the clinic from 2006 to 2008 and mutational prevalences in HIV from patients with discordant tipranavir and darunavir susceptibility phenotypes.
    Bethell R; Scherer J; Witvrouw M; Paquet A; Coakley E; Hall D
    AIDS Res Hum Retroviruses; 2012 Sep; 28(9):1019-24. PubMed ID: 22098079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Halogen Bond Interactions of Novel HIV-1 Protease Inhibitors (PI) (GRL-001-15 and GRL-003-15) with the Flap of Protease Are Critical for Their Potent Activity against Wild-Type HIV-1 and Multi-PI-Resistant Variants.
    Hattori SI; Hayashi H; Bulut H; Rao KV; Nyalapatla PR; Hasegawa K; Aoki M; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30962341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance.
    Ghosh AK; Chapsal BD; Weber IT; Mitsuya H
    Acc Chem Res; 2008 Jan; 41(1):78-86. PubMed ID: 17722874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging HIV-1 resistance to tipranavir and darunavir in patients with virological failure to first-generation protease inhibitors in Taiwan.
    Hsieh SM; Chang SY; Hung CC; Sheng WH; Chen MY; Chang SC
    Int J STD AIDS; 2011 Nov; 22(11):617-20. PubMed ID: 22096044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir.
    Lefebvre E; Schiffer CA
    AIDS Rev; 2008; 10(3):131-42. PubMed ID: 18820715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unique Flap Conformation in an HIV-1 Protease with High-Level Darunavir Resistance.
    Nakashima M; Ode H; Suzuki K; Fujino M; Maejima M; Kimura Y; Masaoka T; Hattori J; Matsuda M; Hachiya A; Yokomaku Y; Suzuki A; Watanabe N; Sugiura W; Iwatani Y
    Front Microbiol; 2016; 7():61. PubMed ID: 26870021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pattern and impact of emerging resistance mutations in treatment experienced patients failing darunavir-containing regimen.
    Delaugerre C; Pavie J; Palmer P; Ghosn J; Blanche S; Roudiere L; Dominguez S; Mortier E; Molina JM; de Truchis P
    AIDS; 2008 Sep; 22(14):1809-13. PubMed ID: 18690163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of drug resistance during HIV RNA viraemia in the MONET trial of darunavir/ritonavir monotherapy.
    Pulido F; Arribas JR; Hill A; Van Delft Y; Moecklinghoff C
    Antivir Ther; 2011; 16(1):59-65. PubMed ID: 21311109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel HIV-1 protease inhibitor, GRL-044, has potent activity against various HIV-1s with an extremely high genetic barrier to the emergence of HIV-1 drug resistance.
    Aoki M; Chang SB; Das D; Martyr C; Delino NS; Takamatsu Y; Ghosh AK; Mitsuya H
    Glob Health Med; 2019 Oct; 1(1):36-48. PubMed ID: 33330753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence for different susceptibility to tipranavir and darunavir in patients infected with distinct HIV-1 subtypes.
    Poveda E; de Mendoza C; Parkin N; Choe S; García-Gasco P; Corral A; Soriano V
    AIDS; 2008 Mar; 22(5):611-6. PubMed ID: 18317002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Yeast cells as a tool for analysis of HIV-1 protease susceptibility to protease inhibitors, a comparative study.
    Ravaux I; Perrin-East C; Attias C; Cottalorda J; Durant J; Dellamonica P; Gluschankof P; Stein A; Tamalet C
    J Virol Methods; 2014 Jan; 195():180-4. PubMed ID: 24056262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients.
    De Meyer S; Lathouwers E; Dierynck I; De Paepe E; Van Baelen B; Vangeneugden T; Spinosa-Guzman S; Lefebvre E; Picchio G; de Béthune MP
    AIDS; 2009 Sep; 23(14):1829-40. PubMed ID: 19474650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Virological characterization of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the ARTEMIS study: 96-week analysis.
    Lathouwers E; De Meyer S; Dierynck I; Van de Casteele T; Lavreys L; de Béthune MP; Picchio G
    Antivir Ther; 2011; 16(1):99-108. PubMed ID: 21311113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DPC 681 and DPC 684: potent, selective inhibitors of human immunodeficiency virus protease active against clinically relevant mutant variants.
    Kaltenbach RF; Trainor G; Getman D; Harris G; Garber S; Cordova B; Bacheler L; Jeffrey S; Logue K; Cawood P; Klabe R; Diamond S; Davies M; Saye J; Jona J; Erickson-Viitanen S
    Antimicrob Agents Chemother; 2001 Nov; 45(11):3021-8. PubMed ID: 11600351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness, durability, and safety of darunavir/ritonavir in HIV-1-infected patients in routine clinical practice in Italy: a postauthorization noninterventional study.
    Antinori A; Meraviglia P; Monforte Ad; Castagna A; Mussini C; Bini T; Gianotti N; Rusconi S; Colella E; Airoldi G; Mancusi D; Termini R
    Drug Des Devel Ther; 2016; 10():1589-603. PubMed ID: 27226708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interpretation of genotypic HIV-1 resistance to darunavir and virological response: validation of available systems and of a new score.
    De Luca A; Di Giambenedetto S; Maserati R; Gianotti N; Narciso P; Antinori A; Di Perri G; Prosperi MC; Baldanti F; Micheli V; Zazzi M; Perno CF; Santoro MM; ;
    Antivir Ther; 2011; 16(4):489-97. PubMed ID: 21685536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patients.
    Dierynck I; De Meyer S; Lathouwers E; Vanden Abeele C; Van De Casteele T; Spinosa-Guzman S; de Béthune MP; Picchio G
    Antivir Ther; 2010; 15(8):1161-9. PubMed ID: 21149923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.